175422-04-5

Basic information

• Product Name: 2,6-DIBROMO-4-NITRO-PYRIDINE
• Synonyms: 2,6-DIBROMO-4-NITRO-PYRIDINE;Pyridine, 2,6-dibromo-4-nitro-;2,6-DIBROMO-4-NITRO-PYRIDINE2;2,6-Dibromo-4-nitropyridine≥ 98% (HPLC)
• CAS NO: 175422-04-5
• Molecular Formula: C₅H₂Br₂N₂O₂
• Molecular Weight: 281.89
• EINECS: -0
• Product Categories: Pyridines
• Mol File: 175422-04-5.mol

Chemical Properties

• Boiling Point: 330.018 °C at 760 mmHg
• Flash Point: 153.389 °C
• Appearance: /
• Density: 2.222 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -7.58±0.10(Predicted)
• CAS DataBase Reference: 2,6-DIBROMO-4-NITRO-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIBROMO-4-NITRO-PYRIDINE(175422-04-5)
• EPA Substance Registry System: 2,6-DIBROMO-4-NITRO-PYRIDINE(175422-04-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 175422-04-5(Hazardous Substances Data)

Usage

Chemical Properties

Pale yellow crystalline powder

Uses

2,6-Dibromo-4-nitropyridine

InChI:InChI=1/C5H2Br2N2O2/c6-4-1-3(9(10)11)2-5(7)8-4/h1-2H

Upstream product

• 98027-81-7 2,6-dibromo-4-nitro-pyridine 1-oxide 
• 626-05-1 2,6-Dibromopyridine 
• 25373-69-7 2,6-dibromopyridin N-oxide 

Downstream Products

• 117873-72-0 2,6-dibromo-4-methoxy pyridine 
• 213674-46-5 4'-Nitro-2,2':6',2''-terpyridine 
• 231287-48-2 2,6-dibromo-4-(4-nitrophenylsulfanyl)-pyridine 
• 871820-11-0 2,6-dibromo-4-(N-methyl-N-octylamino)pyridine 
• 920752-34-7 (2,6-dibromo-pyridin-4-yl)-(2-pyridin-2-yl-ethyl)-amine 
• 192447-61-3 4-{methyl(phenylmethyl)amino}-2,6-dibromo pyridine 
• 920752-37-0 (2,6-dibromo-pyridin-4-yl)-(3-fluoro-biphenyl-2-yl)-amine 
• 920752-41-6 (2-bromo-6-methoxy-pyridin-4-yl)-(3-fluoro-biphenyl-2-yl)-amine 
• 920752-39-2 6-bromo-N²-(2,4-dimethoxy-benzyl)-N⁴-(2-pyridin-2-yl-ethyl)-pyridine-2,4-diamine 
• 920752-40-5 N-biphenyl-3-yl-N''-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-pyridine-2,4,6-triamine 
• 343977-88-8 bis-[2,6-bis(2-pyridyl)-4-pyridyl]diazene 
• 193944-66-0 4′-amino-2,2′:6′,2″-terpyridine 
• 192447-55-5 2,6-dibromo-4-methylmercapto pyridine 
• 193074-42-9 (2,6-dibromo-4-pyridin-4-yl)-methylamine 

Relevant articles and documents

4′-nitro-2,2′:6′,2″-terpyridine, 4′-amino-2,2′:6′,2′-terpyridine and their homo- and heteroleptic iron(II) and ruthenium(II) Complexes

The new ligands 4′-nitro-2,2′:6′,2″-terpyridine and 4′-amino-2,2′:6′,2′-terpyridine and their homoleptic and heteroleptic iron(II) and ruthenium(II) complexes have been prepared and the electrochemistry of the complexes has been investigated.

Interaction of the dihydropyridine/pyridinium redox pair fixed into a V-shaped conformation

A new V-shaped molecule incorporating a dihydropyridine and a pyridinium moiety was synthesized and evaluated for its effect on the interaction between the hydride donor-acceptor pair. Spectroscopic, electrochemical, and computational studies have revealed the presence of the charge transfer interaction as a consequence of the electron donor-acceptor association.

Inhibition of cancer-associated mutant isocitrate dehydrogenases: Synthesis, structure-activity relationship, and selective antitumor activity

Mutations of isocitrate dehydrogenase 1 (IDH1) are frequently found in certain cancers such as glioma. Different from the wild-type (WT) IDH1, the mutant enzymes catalyze the reduction of α-ketoglutaric acid to d-2-hydroxyglutaric acid (D2HG), leading to cancer initiation. Several 1-hydroxypyridin-2-one compounds were identified to be inhibitors of IDH1(R132H). A total of 61 derivatives were synthesized, and their structure-activity relationships were investigated. Potent IDH1(R132H) inhibitors were identified with Ki values as low as 140 nM, while they possess weak or no activity against WT IDH1. Activities of selected compounds against IDH1(R132C) were found to be correlated with their inhibitory activities against IDH1(R132H), as well as cellular production of D2HG, with R2 of 0.83 and 0.73, respectively. Several inhibitors were found to be permeable through the blood-brain barrier in a cell-based model assay and exhibit potent and selective activity (EC50 = 0.26-1.8 μM) against glioma cells with the IDH1 R132H mutation.

MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES

The present invention describes novel indenofluorene derivatives which can preferably be employed as matrix materials for phosphorescent dopants or as electron-transport materials, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to polymers which comprise these compounds as structural units and to a process for the preparation of the compounds according to the invention and to electronic devices which comprise same.

Synthesis of strained pyridine-containing cyclyne via reductive aromatization

The Sonogashira-Hagihara coupling reactions of 2,6-diiodopyridine and cis-3,6-diethynyl-3,6-dimethoxycyclohexa-1,4-diene or cis-9,10-diethynyl-9,10- dimethoxy-9,10-dihydroanthracene gave macrocyclic compounds having alternating 2,6-diethynylpyridine and 3,6-dimethoxycyclohexa-1,4-diene segments. Transformation of the C3-symmetric 2,6-diethynylpyridine-based cyclotrimer was efficiently achieved using tin-mediated reductive aromatization under mild conditions.

Regioselective synthesis of 2,4,6-triaminopyridines

A regioselective synthesis of 2,4,6-trisubstituted pyridine is described starting from 2,6-dibromo-4-nitropyridine. All three different regioisomers of the 2,4,6-triamino substituted pyridine have been synthesized in four to five steps. The method described is a general route to unsymmetrical 2,4,6-trisubstituted amino pyridines.

NOVEL 2,4,6-TRI-SUBSTITUTED HETEROCYCLES AND USES THEREOF

Compounds of formula (I) and (II); their pharmaceutical compositions and methods of use for the treatment of neurological disorders related to amyloid ? protein production such as Alzheimer's disease.

PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES

The invention relates to 6-substituted imidazo[4,5-c]pyridines of formula 1, in which X is O (oxygen) or NH and Y has either the meaning -CH2-AR or Y denotes the group gp (gp) wherein Z has the meaning -CHR8- or -CHR8-CHR9-. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

Influence of the 5-HT6 receptor on acetylcholine release in the cortex: Pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-ht6 receptor antagonist

A small series of aryl pyridyl sulfones has been prepared and investigated for its 5-HT6 receptor binding properties. Thereof, pyrrolidinyl derivative 11 proved to be a very potent (pKi 9) and selective 5-HT6 receptor antagonist. By means of in vivo microdialysis in the frontal cortex and a passive avoidance paradigm, where 11 reversed a scopolamine induced retention deficit, a functional correlation between 5-HT6 receptors and cholinergic neurotransmission could be shown, supporting the therapeutic potential of 5-HT6 receptors in the treatment of cognitive deficits.

7. Lanthanide Complexes of Polyacid Ligands Derived from 2,6-Bis(pyrazol-1-yl)pyridine, Pyrazine, and 6,6′-Bis(pyrazol-1-yl)-2,2′-bipyridine: Synthesis and Luminescence Properties

The synthesis of three novel pyrazole-containing complexing acids, N,N,N′,N′-{2,6-bis[3-(aminomethyl)pyrazol-1-yl]-4-methoxypyridine} tetrakis(acetic acid) (1), N,N,N′, N′-{2,6-bis[3-(aminomethyl)pyrazol-1-yl]pyrazine}tetrakis(acetic acid) (2), and N,N,N′,N′-{6,6′-bist[3-(aminomethyl)pyrazol-1-yl]-2,2′- bipyridine}tetrakis(acetic acid) (3) is described. Ligands 1-3 formed stable complexes with EuIII, TbIII, SmIII and DyIII in H2O whose relative luminescence yields, triplet-state energies, and emission decay lifetimes were measured. The number of H2O molecules in the first coordination sphere of the lanthanide ion were also determined. Comparison of data from the EuIII and TbIII complexes of 1-3 and those of the parent trisheterocycle N,N,N′,N′-{2,6-bis[3-(aminomethyl)pyrazol-1-yl]pyridine} tetrakis(acetic acid) showed that the modification of the pyridine ring for pyrazine or 2,2′-bipyridine strongly modify the luminescence properties of the complexes. MeO Substitution at C(4) of 1 maintain the excellent properties described for the parent compound and give an additional functional group that will serve for attaching the label to biomolecules in bioaffinity applications.